On the Use of Co-Data in Clinical Trials
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2016/07/02
-
Indian UGC (journal)
-
Refrences57
-
Citations38
-
Beat Neuenschwander Novartis Pharma AG, Basel, Switzerland
-
Satrajit Roychoudhury Novartis Pharmaceuticals, East Hannover, NJ, USA
-
Heinz Schmidli Novartis Pharma AG, Basel, Switzerland
Cite
Neuenschwander, Beat, et al. “On the Use of Co-Data in Clinical Trials”. Statistics in Biopharmaceutical Research, vol. 8, no. 3, 2016, pp. 345-54, https://doi.org/10.1080/19466315.2016.1174149.
Neuenschwander, B., Roychoudhury, S., & Schmidli, H. (2016). On the Use of Co-Data in Clinical Trials. Statistics in Biopharmaceutical Research, 8(3), 345-354. https://doi.org/10.1080/19466315.2016.1174149
Neuenschwander B, Roychoudhury S, Schmidli H. On the Use of Co-Data in Clinical Trials. Statistics in Biopharmaceutical Research. 2016;8(3):345-54.
Journal Categories
Medicine
Medicine (General)
Computer applications to medicine
Medical informatics
Science
Biology (General)
Science
Mathematics
Science
Mathematics
Probabilities
Mathematical statistics
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Title | 2010 | |||
| Title | 2003 | |||
| Title | 1984 | |||
| Title | 2015 | |||
| Title | 2015 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
A Bayesian adaptive design for dual‐agent phase I–II oncology trials integrating efficacy data across stages | Biometrical Journal |
| 2023 | |
Alone, together: On the benefits of Bayesian borrowing in a meta‐analytic setting | Pharmaceutical Statistics |
| 2023 | |
| Challenges in Implementing Futility Schemes, with Reference to Aducanumab | Therapeutic Innovation & Regulatory Science |
| 1 | 2023 |
| Copula-Based Model for Incorporating Single-Agent Historical Data into Dual-Agent Phase I Cancer Trials | Statistics in Biopharmaceutical Research |
| 1 | 2023 |
| Coping with Information Loss and the Use of Auxiliary Sources of Data: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions | Statistics in Biopharmaceutical Research |
| 3 | 2023 |
Citations Analysis
The category
Science: Mathematics: Probabilities. Mathematical statistics 25
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Bayesian Phase II optimization for time-to-event data based on historical information and was published in 2017. The most recent citation comes from a 2023 study titled Dynamic Enrichment of Bayesian Small-Sample, Sequential, Multiple Assignment Randomized Trial Design Using Natural History Data: A Case Study from Duchenne Muscular Dystrophy. This article reached its peak citation in 2022, with 9 citations. It has been cited in 20 different journals, 10% of which are open access. Among related journals, the Pharmaceutical Statistics cited this research the most, with 5 citations. The chart below illustrates the annual citation trends for this article.